Skip to main content
SpringerLink
Log in

Peritoneal Carcinomatosis

  • Chapter
Book cover Current Controversies in Cancer Care for the Surgeon

Abstract

The intraabdominal dissemination of neoplasm to the peritoneal surface is referred to as peritoneal carcinomatosis or peritoneal surface disease (PSD). PSD represents localized metastasis that may occur as the initial presentation or as recurrent disease in a number of intraabdominal neoplasms including appendiceal, colon, ovarian, and gastric carcinomas, as well as peritoneal mesothelioma and sarcomas (Table 1). This seeding and subsequent spread may occur secondary to spontaneous tumor rupture or tumor disruption during the initial resection. Intraperitoneal free tumor cells then preferentially deposit on peritoneal surfaces, the diaphragm, and the small bowel mesentery (Fig. 1). As dictated by the aggressiveness of the origin tumor, the number, size, and distribution of the individual tumor deposits on peritoneal surfaces vary greatly. For many causes of PSD, the disease may remain contained in the abdomen, with modest risk of extra-abdominal metastasis. This regional pattern of recurrence makes aggressive therapy in the abdomen with cytoreduction an attractive therapy for many patients with PSD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.

    Article  PubMed  CAS  Google Scholar 

  2. Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–6.

    Article  PubMed  CAS  Google Scholar 

  3. de Bree E, Koops W, Kröger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64–73.

    Article  PubMed  Google Scholar 

  4. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327–33.

    Article  PubMed  Google Scholar 

  5. Stewart 4th JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy current status and future directions. Ann Surg Oncol. 2005;12(10):765–77.

    Article  PubMed  Google Scholar 

  6. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70.

    Article  PubMed  CAS  Google Scholar 

  7. Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;10(5):761–7.

    Article  PubMed  CAS  Google Scholar 

  8. Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology. 1997;204(2):513–20.

    Article  PubMed  CAS  Google Scholar 

  9. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14(3):254–61.

    Article  PubMed  CAS  Google Scholar 

  10. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001;82(1):17–21.

    Article  PubMed  CAS  Google Scholar 

  11. Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98(4):263–7.

    Article  PubMed  Google Scholar 

  12. Rohani P, Scotti SD, Shen P, Stewart JH, Russell GB, Cromer M, et al. Use of FDG-PET imaging for patients with disseminated cancer of the appendix. Am Surg. 2010;76(12):1338–44.

    PubMed  Google Scholar 

  13. Sebbag G, Sugarbaker PH. Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol. 2001;27(3):223–4.

    Article  PubMed  CAS  Google Scholar 

  14. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;35(3):413–9.

    Article  PubMed  CAS  Google Scholar 

  15. Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29(1):69–73.

    Article  PubMed  Google Scholar 

  16. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosisfrom gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124–9.

    PubMed  CAS  Google Scholar 

  18. Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000;88(11):2512–9.

    Article  PubMed  CAS  Google Scholar 

  19. Rey Y, Porcheron J, Talabard JN, Szafnicki K, Balique JG. Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia. Ann Chir. 2000;125(7):631–42.

    Article  PubMed  CAS  Google Scholar 

  20. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19(12):1390–408.

    Article  PubMed  CAS  Google Scholar 

  21. Denzer U, Hoffmann S, Helmreich-Becker I, Kauczor HU, Thelen M, Kanzler S, et al. Minilaparoscopy In the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography. Surg Endosc. 2004;18:1067–70.

    Article  PubMed  CAS  Google Scholar 

  22. Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol. 2006;32(6):625–7.

    Article  PubMed  Google Scholar 

  23. Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(5):540–3.

    Article  PubMed  CAS  Google Scholar 

  24. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256–60.

    PubMed  CAS  Google Scholar 

  25. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5–12.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5):943–53.

    Article  PubMed  Google Scholar 

  27. Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;518:573–87.

    Article  Google Scholar 

  28. Alexander Jr HR, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779–86.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Van Sweringen HL, Hanseman DJ, Ahmad SA, Edwards MJ, Sussman JJ. Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surgery. 2012;152(4):617–24.

    Article  PubMed  Google Scholar 

  30. Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON. 2011;16(1):74–9.

    PubMed  CAS  Google Scholar 

  31. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.

    Article  PubMed  Google Scholar 

  32. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138(1):26–33.

    Article  PubMed  CAS  Google Scholar 

  33. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.

    PubMed  CAS  Google Scholar 

  34. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3 Suppl 4):1–6.

    PubMed  CAS  Google Scholar 

  35. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol. 1985;248(3):F425–35.

    PubMed  CAS  Google Scholar 

  36. Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol. 2011;37(8):719–26.

    Article  PubMed  CAS  Google Scholar 

  37. de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52(2):108–12.

    Article  PubMed  CAS  Google Scholar 

  38. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:1013–9.

    Article  Google Scholar 

  39. Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22:2250–6.

    Article  PubMed  CAS  Google Scholar 

  40. Collins DC. 71,000 human appendix specimens. A final report, summarizing forty years’ study. Am J Proctol. 1963;14:265–81.

    PubMed  CAS  Google Scholar 

  41. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92(1):85–91.

    Article  PubMed  CAS  Google Scholar 

  42. Bradley RF, Stewart 4th JH, Ruseell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at single institution, with literature review. Am J Surg Pathol. 2006;30(5):551–9.

    Article  PubMed  Google Scholar 

  43. Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22(4):1274–9.

    Article  PubMed  Google Scholar 

  44. Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL. Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg. 2010;211(4):526–35.

    Article  PubMed  Google Scholar 

  45. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277–82.

    Article  PubMed  Google Scholar 

  46. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219(2):112–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–31.

    Article  PubMed  CAS  Google Scholar 

  48. Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11(4):393–8.

    Article  PubMed  Google Scholar 

  49. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93(10):1270–6.

    Article  PubMed  CAS  Google Scholar 

  50. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16(7):1903–11.

    Article  PubMed  Google Scholar 

  52. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:576–81.

    Article  PubMed  Google Scholar 

  53. Bijelic L, Kumar AS, Stuart OA, Sugarbaker PH. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract. 2012;2012:163284.

    PubMed  PubMed Central  Google Scholar 

  54. Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740–5.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Farquharson AL, Pranesh N, Witham G, Swindell R, Taylor MB, Renehan A, et al. A phase II studyevaluating the use of concurrentmitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99:591–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, et al. Modern systemic chemotherapy in surgicallyunresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116:316–22.

    Article  PubMed  Google Scholar 

  57. Confuorto G, Giuliano ME, Grimaldi A, Viviano C. Peritoneal carcinomatosis from colorectal cancer: HIPEC? Surg Oncol. 2007;16 Suppl 1:S149–52.

    Article  PubMed  Google Scholar 

  58. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–7.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.

    Article  PubMed  Google Scholar 

  60. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.

    Article  PubMed  Google Scholar 

  61. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh 3rd HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62.

    Article  PubMed  Google Scholar 

  62. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Society of Surgical Oncology Annual Meeting. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14(1):128–33.

    Article  PubMed  CAS  Google Scholar 

  63. Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.

    Article  PubMed  Google Scholar 

  64. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.

    Article  PubMed  CAS  Google Scholar 

  65. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–8.

    Article  PubMed  Google Scholar 

  66. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5.

    Article  PubMed  Google Scholar 

  67. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.

    Article  PubMed  CAS  Google Scholar 

  68. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43:S15–25.

    Article  PubMed  Google Scholar 

  69. Chua TC, Yan TD, Zhao J, Morris DL. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol. 2009;35(12):1299–305.

    Article  PubMed  CAS  Google Scholar 

  70. Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol. 2006;32(6):632–6.

    Article  PubMed  CAS  Google Scholar 

  71. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245(4):597–603.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Verwaal VJ, Kusamura S, Baratti D, Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):220–3.

    Article  PubMed  Google Scholar 

  73. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015. http://seer.cancer.gov/csr/1975_2012/.

    Google Scholar 

  74. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.

    Article  PubMed  CAS  Google Scholar 

  75. Munnell EW. The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol. 1968;100:790–805.

    Article  PubMed  CAS  Google Scholar 

  76. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovariancancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47:159–66.

    Article  PubMed  CAS  Google Scholar 

  77. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol. 2001;82:489–97.

    Article  PubMed  CAS  Google Scholar 

  78. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  79. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    Article  PubMed  CAS  Google Scholar 

  80. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135(12):1637–45.

    Article  PubMed  Google Scholar 

  81. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.

    Article  PubMed  CAS  Google Scholar 

  82. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7–12.

    PubMed  Google Scholar 

  83. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  PubMed  CAS  Google Scholar 

  84. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16:2315–20.

    Article  PubMed  Google Scholar 

  85. Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol. 2002;128:153–60.

    Article  PubMed  CAS  Google Scholar 

  86. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systemic review of clinical management and biologic research. J Surg Oncol. 2011;103(8):822–31.

    Article  PubMed  Google Scholar 

  87. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Oncol. 2007;18:827–34.

    Article  PubMed  CAS  Google Scholar 

  88. Blackham AU, Levine EA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Clin Med Oncol. 2012;4(2):25–32.

    Google Scholar 

  89. Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8(1):35–9.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13.

    Article  PubMed  Google Scholar 

  91. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40–6.

    Article  PubMed  Google Scholar 

  92. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93.

    Article  PubMed  Google Scholar 

  93. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.

    Article  PubMed  Google Scholar 

  94. Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22(5):1680–5.

    Article  PubMed  Google Scholar 

  95. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229–37.

    Article  PubMed  Google Scholar 

  96. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405–12.

    Article  PubMed  CAS  Google Scholar 

  97. Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17(10):2720–7.

    Article  PubMed  Google Scholar 

  98. Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98(4):268–72.

    Article  PubMed  Google Scholar 

  99. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1093–100.

    Article  PubMed  Google Scholar 

  100. Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol. 2014;40(5):529–35.

    Article  PubMed  CAS  Google Scholar 

  101. Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(1):53–8.

    Article  PubMed  CAS  Google Scholar 

  102. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10(2):155–62.

    Article  PubMed  Google Scholar 

  103. Duckworth KE, McQuellon RP, Russell GB, Cashwell CS, Shen P, Stewart JH, et al. Patient reported outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). J Surg Oncol. 2012;106(4):376–80.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18(13):3673–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA

    Michelle L. Bryan M.D., Ph.D., Konstantinos I. Votanopoulos M.D., Ph.D., Perry Shen M.D. & Edward A. Levine M.D.

  2. Department of Surgery, Louisiana State University Health Sciences Center, 1501 Kings Highway, New Orleans, LA, 71103, USA

    Shuja Ahmed M.D.

  3. Department of Surgery, Duke University School of Medicine, 3118, Durham, LC, 27710, USA

    John H. Stewart IV M.D., M.B.A

Authors
  1. Michelle L. Bryan M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuja Ahmed M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Konstantinos I. Votanopoulos M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Perry Shen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edward A. Levine M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John H. Stewart IV M.D., M.B.A
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John H. Stewart IV M.D., M.B.A .

Editor information

Editors and Affiliations

  1. Division of Gastrointestinal and Laparoscopic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA

    Katherine A. Morgan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bryan, M.L., Ahmed, S., Votanopoulos, K.I., Shen, P., Levine, E.A., Stewart, J.H. (2016). Peritoneal Carcinomatosis. In: Morgan, K. (eds) Current Controversies in Cancer Care for the Surgeon. Springer, Cham. https://doi.org/10.1007/978-3-319-16205-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16205-8_11

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16204-1

  • Online ISBN: 978-3-319-16205-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation